Novel agents that downregulate EGFR, HER2, and HER3 in parallel

@inproceedings{Ferreira2015NovelAT,
  title={Novel agents that downregulate EGFR, HER2, and HER3 in parallel},
  author={Renan Barroso Ferreira and Mary Elizabeth Law and Stephan Christopher Jahn and Bradley John Davis and Coy Don Heldermon and Mary K. Reinhard and Ronald K Castellano and Brian Keith Law},
  booktitle={Oncotarget},
  year={2015}
}
EGFR, HER2, and HER3 contribute to the initiation and progression of human cancers, and are therapeutic targets for monoclonal antibodies and tyrosine kinase inhibitors. An important source of resistance to these agents arises from functional redundancy among EGFR, HER2, and HER3. EGFR family members contain conserved extracellular structures that are… CONTINUE READING